Cited by 78Colorectal Cancer Surgical TreatmentsCOVID-19 and healthcare impactsColorectal and Anal Carcinomas

International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic

Open access
Marijnen, C.A.M., Peters, F.P., Rödel, C., Bujko, K., Haustermans, K., Fokas, E., Glynne-Jones, R., Valentini, V. +7 more·2020·Radiotherapy and Oncology

Abstract

The rapid spread of COVID19 infection across the globe is causing a health care emergency. Our aim is to assist discussion about the risks and benefits to facilitate decision-making regarding radiotherapy for rectal cancer patients. In our roles as clinicians and as experts who have conducted clinical trials evaluating the role of radiotherapy in rectal cancer, we present our assessment of treatment options that should be considered by health care professionals in the setting of the COVID 19 pandemic. We want to minimize the risks to our patients whilst aiming to maintain cancer outcomes. We have used the European Society for Medical Oncology (ESMO) rectal cancer guidelines as a framework to describe our recommendations [[1]Glynne-Jones R. Wyrwicz L. Tiret E. et al.Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2017; 28 (iv22-iv40)Abstract Full Text Full Text PDF Scopus (1109) Google Scholar] (Fig. 1). ESMO Guideline: TME without pre-operative radiotherapy is recommended in most cases. Recommendation: We strongly support the use of TME without pre-operative radiotherapy. ESMO Guideline: TME alone or SCRT/CRT if good quality mesorectal excision cannot be assured. Recommendation: In countries where high quality surgery is performed, we strongly recommend TME alone. Careful discussion of the use of radiotherapy in this group is needed in the COVID 19 setting where the benefits of preoperative radiotherapy are likely to be small. If radiotherapy is to be used, SCRT should be the preferred option rather than CRT (see below). ESMO Guideline: Pre-operative SCRT or CRT is recommended. Recommendation: We strongly recommend the use of SCRT. Two phase III trials have compared SCRT and CRT and demonstrate comparable outcomes for local recurrence, disease free survival (DFS), overall survival (OS) and late toxicity [2Ngan S.Y. Burmeister B. Fisher R.J. et al.Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04.J Clin Oncol. 2012; 30: 3827-3833Crossref PubMed Scopus (657) Google Scholar, 3Bujko K. Nowacki M.P. Nasierowska-Guttmejer A. Michalski W. Bebenek M. Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer.Br J Surg. 2006; 93: 1215-1223Crossref PubMed Scopus (1004) Google Scholar]. Both approaches are widely used. In the COVID 19 setting there are some important factors to consider. When the use of SCRT is compared with CRT there are many advantages of SCRT:- less acute toxicity; fewer radiotherapy treatment attendances; substantial reduction in travel and contact with other patients and staff; avoidance of any detrimental effect of concurrent chemotherapy on immune function; and thus significantly reduced risk of COVID 19 infection during treatment. The greater social distancing achieved with SCRT is a major advantage. An additional benefit is that the use of SCRT instead of CRT in this setting will have a substantial reduction in linear accelerator usage, will help avoid waiting time to start treatment and increase the ability of departments to treat all their patients in the setting of reduced staffing levels. ESMO Guideline: Not stated as the Stockholm III trial was published post guideline. Recommendation: SCRT and a delay to surgery has advantages that may be beneficial in both routine clinical practice and in the COVID 19 setting. The Dutch TME and MRC CR07 trials as well as the previous Swedish trials recommended that surgery should be performed within three to seven days of completion of SCRT [4van Gijn W. Marijnen C.A. Nagtegaal I.D. et al.Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial.Lancet Oncol. 2011; 12: 575-582Abstract Full Text Full Text PDF PubMed Scopus (1372) Google Scholar, 5Sebag-Montefiore D. Stephens R.J. Steele R. et al.Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.Lancet. 2009; 373: 811-820Abstract Full Text Full Text PDF PubMed Scopus (1246) Google Scholar, 6Folkesson J. Birgisson H. Pahlman L. Cedermark B. Glimelius B. Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate.J Clin Oncol. 2005; 23: 5644-5650Crossref PubMed Scopus (687) Google Scholar]. The recently reported Stockholm III trial compared surgery performed within one week with 4–8 weeks after SCRT [[7]Erlandsson J. Holm T. Pettersson D. et al.Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiori

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.radonc.2020.03.039

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Marijnen, C. A. M., Peters, F. P., Rödel, C., Bujko, K., Haustermans, K., Fokas, E., Glynne-Jones, R., Valentini, V., Spindler, K.-L. G., Guren, M. G., Maingon, P., Calvo, F. A., Pares, O., Glimelius, B., & Sebag-Montefiore, D.
Affiliations
  • Leiden University Medical Center (NL)
  • Goethe University Frankfurt (DE)
  • The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
  • Universitair Ziekenhuis Leuven (BE)
  • Università Cattolica del Sacro Cuore (IT)
  • Aarhus University Hospital (DK)
  • Oslo University Hospital (NO)
  • Sorbonne Université (FR)
  • Uppsala University (SE)
Venue
Radiotherapy and Oncology
Publisher
Elsevier BV
Published
2020-07
Volume
148
Pages
213-215
ISSN
0167-8140 (ISSN-L)
OpenAlex
W3013670950
Cited by
78
References
10
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 5 · 2022: 11 · 2021: 16 · 2020: 38
Type
journal article
Language
en
Open access
Locations
  • Radiotherapy and Oncology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Lirias (submittedVersion, other-oa)
Funders
Cancer Research UK (28832, 25447)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
  • Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
Keywords
rectal cancer, radiotherapy, COVID-19 pandemic, treatment options, total mesorectal excision, short-course radiotherapy, chemoradiotherapy, preoperative radiotherapy, local recurrence, treatment prioritization, patient safety, ESMO guidelines, clinical guidelines, late toxicity, disease-free survival, overall survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review